

MODERN SLAVERY AND HUMAN TRAFFICKING STATEMENT
SUNOVION PHARMACEUTICALS EUROPE LIMITED

INTRODUCTION

This statement, made pursuant to section 54(1) of the Modern Slavery Act 2015, constitutes our slavery and human trafficking statement for the financial year ending 31 March 2018 and sets out the steps taken by Sunovion Pharmaceuticals Europe Limited. (Sunovion Europe) to ensure that slavery and human trafficking is not taking place in any of its supply chains or any part of its business. As a member of the pharmaceutical industry, we understand that we have a responsibility to maintain high ethical standards, to conduct our business in a transparent and fair manner, and to comply with all applicable laws and regulations. In this context, we are committed to ensuring that our business and supply chain is free from slavery and human trafficking.

ORGANISATION'S STRUCTURE AND OUR BUSINESS

Sunovion Europe, headquartered in London, is a wholly-owned subsidiary of Sunovion Pharmaceuticals Inc. in the United States, which in turn is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., whose head office is in Japan.

Sunovion Europe is a pharmaceutical company focused on the development and introduction of innovative medicines that improve people's health and wellbeing. We currently specialise in Psychiatry and Neurology - including mental health - and other areas of unmet medical need that require highly specialised drug development. We work together with our colleagues globally to develop and introduce innovative medicines in Europe.

OUR SUPPLY CHAINS

Our supply chains include all aspects relevant to the research, manufacture and supply of pharmaceutical products. Our products are sourced from Sumitomo Dainippon Pharma in Japan and several third party manufacturers and suppliers from Europe, Japan and the U.S. (our Business Partners) and packaged and sold in the U.K.

Our Corporate Values, Policies and Procedures

Sunovion's mission is to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. We will achieve this by discovering, developing and commercializing scientifically advanced pharmaceutical products.

The Sunovion Code of Conduct and Ethics provides the framework under which we integrate our mission into our daily activities – both as employees of our company and members of the communities where we conduct business.

All employees are expected to understand and uphold our Code of Conduct and Ethics including complying with all applicable laws, acting ethically and making business decisions that are consistent with our policies, procedures and values.

The Sunovion Code includes commitments to good corporate citizenship and to creating a workplace environment that is welcoming, safe and respectful. This commitment extends to all of our dealings, including those with customers, suppliers and outside business partners.

To facilitate compliance we have established a phone and web-based Ethics Hotline where employees can ask questions or raise any concerns regarding potential violations of law, industry standards or our Code of Conduct and Ethics.

ACTIONS TAKEN TO DATE

As a company committed to compliance with all applicable laws and regulations, Sunovion Europe is dedicated to ensuring that there is no slavery or human trafficking in our supply chains or in any part of our business. We have sought to ensure that our supply chains are free from slavery and human trafficking, by taking steps that include contract terms with our Business Partners that require them to comply with applicable laws, including labour laws. In addition, the company has a dedicated compliance team and program in place to ensure that we adhere to applicable laws, including local labour standards and extend our Ethics Hotline to third-parties with a commitment to protecting the anonymity of reporters (if requested) and non-retaliation. The company is introducing an online training course on principles of compliance with the Modern Slavery Act. The course will be rolled out to all current employees and will form part of the on boarding process for new employees.

FURTHER STEPS


We have reviewed the effectiveness of the steps we have taken this year to ensure that there is no slavery or human trafficking in our supply chains and we intend to take the following further steps to combat slavery and human trafficking:

We intend to include modern slavery and human trafficking into the roster of risks that we assess during our annual risk assessment and will consider steps to mitigate risks if necessary.

Sunovion Europe also intends to assess the Modern Slavery Act compliance efforts of prospective Business Partners as part of our due diligence process.

If Sunovion Europe becomes aware that a Business Partner has failed to comply with our supply chain values with respect to modern slavery or human trafficking, we will take appropriate corrective action, which might include terminating the business relationship.

Signed



Terry Petersen

Sunovion Pharmaceuticals Europe Limited.

Date: 30th June 2018